Health Yuan: La inyección de hormona folículo estimulante recombinante humana de Lizhu monoclonal ha obtenido la aprobación de registro, con gastos de investigación y desarrollo de aproximadamente 122 millones de yuanes

robot
Generación de resúmenes en curso
Health Yuan announces that recently, its subsidiary Zhuhai Lijubantibody Biotechnology Co., Ltd., a subsidiary of Lijubao Pharmaceutical Group Co., Ltd., received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration.
The generic name of the drug is recombinant human follicle-stimulating hormone injection, and the trade name is Liyoubao.
Indications include women with anovulation, women undergoing superovulation in assisted reproductive technology, and patients with severe deficiency of luteinizing hormone and follicle-stimulating hormone.
This product is produced using recombinant gene technology, and clinical Phase I to III evaluations of biosimilar drugs have been completed, demonstrating equivalence with the original drug.
As of the announcement date, the total direct R&D expenses invested in this product are approximately 122 million yuan.
Ver original
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
  • Recompensa
  • Comentar
  • Republicar
  • Compartir
Comentar
Añadir un comentario
Añadir un comentario
Sin comentarios
  • Fijado